Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Nektar Therapeutics (NASDAQ: NKTR) was $1.12 for the day, down -0.88% from the previous closing price of $1.13. In other words, the price has decreased by -$0.88 from its previous closing price. On the day, 1.14 million shares were traded. NKTR stock price reached its highest trading level at $1.175 during the session, while it also had its lowest trading level at $1.08.
Ratios:
Our analysis of NKTR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 5.15. In the meantime, Its Debt-to-Equity ratio is 2.76 whereas as Long-Term Debt/Eq ratio is at 2.49.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $2.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 19 ’24 when Zalevsky Jonathan sold 6,866 shares for $1.28 per share. The transaction valued at 8,788 led to the insider holds 250,804 shares of the business.
Wilson Mark Andrew sold 5,651 shares of NKTR for $7,233 on Aug 19 ’24. The Chief Legal Officer now owns 225,263 shares after completing the transaction at $1.28 per share. On Aug 19 ’24, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 14,881 shares for $1.28 each. As a result, the insider received 19,048 and left with 848,358 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 206168496 and an Enterprise Value of 154540016. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.21 while its Price-to-Book (P/B) ratio in mrq is 2.59. Its current Enterprise Value per Revenue stands at 1.659 whereas that against EBITDA is -1.201.
Stock Price History:
Over the past 52 weeks, NKTR has reached a high of $1.93, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is -12.35%, while the 200-Day Moving Average is calculated to be 8.79%.
Shares Statistics:
NKTR traded an average of 1.62M shares per day over the past three months and 870560 shares per day over the past ten days. A total of 191.38M shares are outstanding, with a floating share count of 177.81M. Insiders hold about 3.41% of the company’s shares, while institutions hold 71.63% stake in the company. Shares short for NKTR as of 1723680000 were 8473759 with a Short Ratio of 5.22, compared to 1721001600 on 9724532. Therefore, it implies a Short% of Shares Outstanding of 8473759 and a Short% of Float of 5.89.
